Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94.6 EUR | -1.05% | -5.02% | -7.62% |
Apr. 30 | Vetoquinol: down after sales update | CF |
Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.62% | 1.21B | - | ||
-9.19% | 6.67B | B- | ||
+24.75% | 3.7B | B- | ||
-1.11% | 3.21B | B- | ||
+6.08% | 1.52B | - | ||
-15.13% | 1.37B | B | ||
-25.63% | 1.24B | C- | ||
-10.84% | 1.17B | - | ||
-.--% | 1.05B | - | ||
-7.07% | 832M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VETO Stock
- Ratings Vetoquinol SA